Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds

Preview J&J (JNJ) Q2 earnings July 15: EPS/revenue estimates, segment sales outlook, Stelara risk, and guidance updates—get the key takeaways now.

Johnson & Johnson (JNJ) is expected to report upbeat second quarter results on July 15, before market open, with analysts expecting the firm to post a ~3% Y/Y jump in earnings. Wall Street sees per-share earnings of $2.85 the consensus To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding.

Please disable your ad-blocker and refresh. Entering text into the input field will update the search result below Entering text into the input field will update the search result below Quick Insights Analysts expect positive results, with upbeat earnings and revenue growth likely to improve sentiment, given strong historical performance and raised guidance. Stelara sales are decreasing and could jeopardize meeting future sales targets if the decline outpaces expectations, though it's a smaller revenue component than before.

Investors should focus on the oncology and neuroscience portfolios, which remain key growth drivers amid evolving product mix.